Slides
Page 1
CollPlant Corporate Presentation Nasdaq: CLGN 2026
Page 2
The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and are expected to be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company’s history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company’s expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink and prod ucts for medical aesthetics; the Company’s ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInkan d medical aesthetics products including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company’s rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the Company’s reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company’s ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected. capital expenditures and liquidity; changes in the Company’s strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward- looking statements, see the “Risk Factors” section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. 2 Forward-Looking Statements
Page 3
About CollPlant A regenerative and aesthetic medicine company Developing innovative technologies and products for tissue regeneration and organ manufacturing The Company's products and candidates are based on rhCollagen that is produced in genetically engineered tobacco plants Strategic agreement with global, top-tier pharmaceutical company AbbVie NASDAQ: CLGN, listed since 2018 3
Page 4
Collagen is an Essential Component of the Human Body *(e.g. cartilage, bones, tendons, ligaments, skin and vasculature) 4 25% to 35% of the whole-body protein content Ideal scaffolding molecule for regenerative medicine The main structural protein in the extracellular matrix found in the body’s organs and various connective tissues*
Page 5
N- propeptide C- propeptide COL1⍺1 COL1⍺2 P4H⍺ P4Hß LH3 Our Technology Platform Produces Human Collagen in Plants at Mass-Scale 5
Page 6
Animal ExtractedPlant-derived Clear advantages over tissue-extracted (animal-derived) collagen 6 rhCollagen: The Ideal Building Block for Regenerative Medicine Superior homogeneity: allows for creating implants and biological inks with distinct physical properties Improved safety; does not elicit immune response that would cause implant rejection Xeno-free: sourced from tobacco plants Better biofunctionality: leads to faster tissue repair = Cell binding domains
Page 7
Product Use Preclinical Clinical Commercial Status/Partner Aesthetic medicine Photocurable filler Dermal/soft tissue fillers Regenerative medicine Breast implants Breast reconstruction and augmentation Soft Tissue Repair & BioInks Tissues, organs, drug discovery and tissue modelling How We Are Applying Our rhCollagen: Areas of Focus 7 Injectable tissue fillers Dermal/soft tissue fillers * AbbVie is collecting data and conducting a review of interim results from the first cohort of patients enrolled in the dermal and soft tissue filler clinical trials initiated in 2023 and next steps for the program are to be determined upon complete assessment.
Page 8
8 Dermal/Soft Tissue Fillers In collaboration with
Page 9
9 Dermal Fillers: Market Overview ~5.3M Hyaluronic Acid procedures in 2023 in the US1 $6.3B, 10.3% CAGR Global dermal filler market, 2023, CAGR 2023-20332 $100-$250/unit Cost per syringe3 2% 4% 4% 77% 6% 7% Polymethyl methacrylate microspheres Fat Polylactic acid Hyaluronic acid Calcium Hydroxylapatite PRP 2020 Procedure breakdown, U.S (by material)4 1. The American Society of Plastic Surgeons®, 2023 Procedural Stats Release 2. https://finance.yahoo.com/news/dermal-filler-market-reach-16-151000525.html 3. www.medicalsparx.com/juvederm-hydrate 4. www.medicalsparx.com/buy-juvederm-ultra-plus-xc
Page 10
Combining the Advantages of Collagen and Hyaluronic Acid 10 Biological properties • Promotes cell adhesion and proliferation • Promotes tissue regeneration • Non allergic/non immunogenic HA Physical properties • Highly viscous: Provides mechanical stability after injection • Convenient injection: 37-32G needle, 10-15N expression force • High lifting capacity • Transparent rhCollagen The best of both worlds
Page 11
11 Collaboration Agreement with AbbVie Agreement Highlights Financial Highlights A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market Combines CollPlant’s proprietary rhCollagen technology and AbbVie's technology AbbVie is leading the program and responsible for all development, regulatory and commercialization costs Up to $50M in potential payments for the Dermal filler. Paid by today: $14M upfront payment $10M – achievement of the first milestone in June 2023 $2M achievement of a milestone in February 2025. - Up to additional $20M in milestones Meaningful royalties on all products sales CollPlant will manufacture and sell to AbbVie the rhCollagen used in its dermal filler products *CollPlant started working with Allergan – AbbVie in 2018
Page 12
Photocurable Regenerative Dermal Filler 12
Page 13
13 Introducing CollPlant State-of-the-Art Photocurable Regenerative Soft Tissue Filler Photocurable filler comprised of rhCollagen and hyaluronic acid, injected in a semi-solid phase, hardened in-situ by light illumination Filler Features: Contouring and regeneration may apply to other body areas Ideal solution for “Ozempic Face” indications Allows for regeneration and rejuvenation, extending effects and satisfaction with each injection Enhanced lifting capacity Adhesion and retention to the host tissue Allows for contouring for a natural looking outcome Injection Sculpting Photocuring in-situ
Page 14
14 High Elasticity High Moldability High Cohesivity High Flexibility A Photocurable Dermal Filler would be an all-in-one innovation: Flexibility compliance with facial expression Moldability precise contour definition Cohesivity maintains the defined shape Elasticity Recovers original shape (aligned with facial expression)
Page 15
15 15 KOL Testimonial* Dr. Jason Bloom MD, FACS BLOOM FACIAL PLASTIC SURGERY • “The first injectable moldable implant” • “Provides cohesivity and structural support that far exceeds anything in the market” • “A customizable implant that can be implanted in the office with a minimally invasive procedure.” • “Huge advance in the dermal and soft tissue market, and facial plastic surgery” • “Long lasting results” • “Game changer for facial plastic surgery and soft tissue filler” https://www.bloomfacialplastics.com/ Full video at: https://www.youtube.com/watch?v=D114gdmrdek Use is experimental only at physician’s discretion. CollPlant’s photocurable filler is not yet FDA-approved. * Following Use of Photocurable Dermal Filler
Page 16
16 16 KOL Testimonial Dr. Sachin M. Shridharani, MD, FACS Director - LUXURGERY (New York, NY) • “It changes the overall approach of long-lasting facial sculpting” • “Transforming an injectable filler into a solid-like gel” • “It forms an elastic, cohesive and integrated piece” • “Increased G’, cohesivity, longevity, tissue regeneration” • “Compatible for off-the-face areas” • “Nothing like this is observed with available fillers” https://www.luxurgerynyc.com/dr-shridharani/ Full video at: https://youtu.be/FvdcfO5sQTw Use is experimental only at physician’s discretion. CollPlant’s photocurable filler is not yet FDA-approved. * Following Use of Photocurable Dermal Filler
Page 17
Commercial Product Portfolio 17
Page 18
18 3DBioprinting technologies BioInkCom ponents Direct Ink Writing (DIW) Inkjet Projection Stereolithography Laser Induced Forward Transfer (LIFT) Polymers (physical properties) Ceramics (hard tissue) Nanoparticles (sustained release/physical properties( ECM components (biological/ physical properties) CollInk-3D 20ml rhCollagen BioInk components
Page 19
rhCollagen-based Bioink Platform for Biofabrication Animal-free: excellent safety profile, non immunogenic Optimal rheology at room temperature Cytocompatible, Biofunctional Compatible with major printing technologies Mass production- consistency robustness High homogeneity reproducibility 19
Page 20
Phasing Out Animal Testing FDA Announcement • CollPlant’s novel rhCollagen-based portfolio of BioInk products supports the FDA’s NAMs since they can be used in a wide variety of non-animal testing applications. • CollPlant’s BioInk products are ideal for the biofabrication of tissue/organ-on-a- chip systems used for drug discovery and regenerative medicine applications and are designed to be compatible with human organoids. • We anticipate that our BioInks will be instrumental to enable alternatives for achieving the goal of phasing out animal testing in five years.” 20 https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase- out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs FDA NEWS RELEASE FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs For Immediate Release: April 10, 2025 Today, the U.S. Food and Drug Administration is taking a groundbreaking step to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human- relevant methods. The new approach is designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation, lowering research and development (R&D) costs, and ultimately, drug prices. The FDA’s animal testing requirement will be reduced, refined, or potentially replaced using a range of approaches, including AI-based computational models of toxicity and cell lines and organoid toxicity testing in a laboratory setting (so-called New Approach Methodologies or NAMs data). Implementation of the regimen will begin immediately for investigational new drug (IND) applications, where inclusion of NAMs data is encouraged, and is outlined in a roadmap also being released today. To make determinations of efficacy, the agency will also begin use pre-existing, real-world safety data from other countries, with comparable regulatory standards, where the drug has already been studied in humans.
Page 21
21 Vergenix STR – Orthobiologics PRP collection tube from any commercial PRP Kit Platelet-Rich Plasma Red Blood Cells • Intended for treatment of tendinopathy • Provides: - Localization of platelets at the injury site - Extended therapeutic effect of growth factors • A single application is all that is required to initiate the healing process marked Zhou Y and Wang J: PRP Treatment Efficacy for Tendinopathy: A Review of Basic Science Studies, BioMed Research International, Vol 2016, Article ID 9103792 Worldwide Tendinitis Treatment Market 2018 – Market Size, Analysis, Share, Research, Growth, Market Research Future • 40 patients, single arm, single treatment, 3- & 6-month f/u • End points – Safety; recovery in pain and motion as measured through PRTEE, Quality of Life questionnaire and grip strength test Steroids VergenixSTR 86% 6M 74% 3M 36% 6M48% 3M Clinical study 1 Comparison to steroids derived from reported results in American Journal of Sports Medicine and are not an actual head-to-head clinical trial; if this were a head-to-head clinical trial, outcomes may be different . in the sales phase in Europe
Page 22
22 Vergenix STR Clinical outcomes Significant advantages over standard of care • 40 patients, single arm, single treatment, 3- & 6-month f/u • End points – Safety; recovery in pain and motion as measured through PRTEE, Quality of Life questionnaire and grip strength test Steroids VergenixSTR 86% 6M 74% 3M 36% 6M48% 3M 74% of patients show clinical success at 3M 86% of patients show clinical success at 6M Clinical study* PMS*** * Uri Farkash et al, J Shoulder Elbow Surg (2018) ** Peerbooms JC et al, Am J Sports Med. 2010 , Feb;38(2):255-62 *** Source for PMS data – Arthrex Surgical Outcome System registry ** 0 1 2 3 4 5 6 7 8 9 10 Pre-treatment 2 weeks 6 weeks 3 months 6 months 1 year Visual Analog Pain Score (VAS) Knee Shoulder Elbow Pain reduction 0 10 20 30 40 50 60 70 80 90 100 Pre-treatment 3 months 6 months 1 year SANE Score# Knee Shoulder Elbow #Single Assessment Numerical Assessment Improved patient functionality
Page 23
3D Bioprinting Represents a Wide Range of Development Opportunities 23 Develop in-house or with collaborators Develop in collaboration with leading life sciences companies Developmentcost Timeto market Tissues • Breast • Heart valve • Cornea • Skin • Cartilage Endocrineglands • Ovary • Pancreas • Thyroid Organs • Lungs • Kidney • Liver • HeartScaffolds • Spine fusion • Tendons, ligaments • Bones • Nerve conduits Personalizedmedicine • Drug screening • Tissue models
Page 24
24 3D-bioprinted Regenerative Breast Implants
Page 25
Revolutionary Option: The Ability to Regenerate Breast Tissue * https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast- implant-associated-anaplastic-large-cell-lymphoma No regenerative breast implant exists Safety issues exist with silicone breast implants FDA Alert: Patientswith breast implantshave an increased risk of developingbreast implantAssociated- AnaplasticLarge Cell Lymphoma (June 2023)* 25
Page 26
26 Breast Implant Market Overview 1. www.imarcgroup.com/breast-implant-market 2. www.webmd.com/beauty/cosmetic-procedures-breast-augmentation#1 3. https://finance.yahoo.com/news/global-breast-implants-market-report- 133700143.html 60% Breast Augmentation21% Breast Lift Reconstruction Procedure (US segmentation) $3.0B Market worldwide (2024)1 $ 5-10K Cost per full procedure in US2 ~2,200,000 Breast implant procedures WW (2022) 3
Page 27
27 CollPlant’s 3D Bioprinted Breast Implants 3D printed Breast scaffold: rhColl-MA based formulation Printed implant Implantation and vascularization Implant replacement by newly formed tissue Implant design using M&S* methodologies * M&S – Modeling & Simulation
Page 28
Our Solutions For Advancing Medicine Without Animals 28 FDA “New Approach Methodologies” (NAMS): Designed to improve drug safety and accelerate the evaluation process while reducing animal testing Mayo Clinic Devises First-Ever Skin-on-a Chip: Published in the Archives of Dermatological Research – the first fully humanized 3D bioprinted skin model using CollPlant’s rhCollagen. The model has broad potential as an alternative to animal testing with potential applications in cosmetic and pharmaceutical testing, disease modeling and drug development. (10/16/2025) rhCollagen-based BioInks: Collink.3D portfolio of BioInk products can be used in a wide variety of non-animal testing applications (tissue-on-a-chip or organ-on-a-chip systems) Matrigel Head-to-Head Study Conducted by Levenberg Lab at Technion – Israel Institute of Technology - Collink.3D demonstrated enhanced mechanical strength, elasticity and stability in a head-to-head study against Matrigel®*, a gold standard biomaterial used for cell culture, disease modeling and drug discovery. (10/20/2025) Computational Modeling and Simulation (CM&S) Methodologies: Enables the precise prediction of the mechanical behavior of the regenerative breast implant product candidate in the body to assist with its development. *Matrigel is developed and marketed by Corning and derived from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma
Page 29
Seasoned Management Team with Engineering, Pharmaceutical, Device and Life Sciences Experience 29 Yehiel T al CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Healthcare Tech., CFO (Nasdaq) & Gamida, E&Y Jasmine Seror, PhD VP Product Development Weizmann Institute of Science Oren Fahimipoor VP Operations Omrix Biopharmaceuticals (J&J) Teva Pharmaceutical Industries Ltd Philippe Bensimon PharmD VP RA/QA/CA Maquet Getinge 3M Medical Hadas Dreiher- Horowitz VP HR Elbit Systems Teva Pharmaceutical Industries Ltd Mul-T-Lock Bar Abelis VP Legal Affairs Goldfarb Gross Seligman
Page 30
Investment Summary 30 Pioneering Proprietary, Plant- Based Technology Platform The only commercially viable technology that can produce truly human collagen at mass scale and without reliance on animal tissue Addressing Multi- billion-dollar markets Innovative rhCollagen technology initially focused on medical aesthetic applications; differentiated, transformative, next- generation soft tissue filler is regenerative Broadly applicable, clinically validated technology Ideal building block/scaffolding molecule for regenerative medicine that has clear benefits over tissue-extracted collagen and the potential to create first-in-class products, extend product life cycles and expand applications in other areas of medicine Strategic agreement with global top- tier pharmaceutical company AbbVie Allows for up to $50M in milestone payments plus additional royalties on sales Highly seasoned management team With experience spanning the areas of bioengineering, biomaterials, broad life sciences, pharmaceuticals and devices In-house, sustainable production capabilities In-house cGMP production facility that utilizes proprietary manufacturing processes under environmentally responsible guidelines
Page 31
Thank you!